Seeing Is Believing
Currently out of the existing stock ratings of Yifeng Liu, 2 are a SELL (28.57%), 4 are a HOLD (57.14%), 1 are a BUY (14.29%).
Analyst Yifeng Liu, currently employed at HSBC, carries an average stock price target met ratio of 75% that have a potential upside of 13.86% achieved within 276 days.
Yifeng Liu’s has documented 12 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MRNA, Moderna at 18-Nov-2024.
Analyst best performing recommendations are on BNTX (BIONTECH SE).
The best stock recommendation documented was for BNTX (BIONTECH SE) at 3/22/2024. The price target of $90 was fulfilled within 13 days with a profit of $1.83 (1.99%) receiving and performance score of 1.53.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Mar-2025
$105
$8.27 (8.55%)
$143
Buy Since 14-Nov-2024
$136
$39.27 (40.60%)
$171
12 days ago
(31-Aug-2026)
0/5 (0%)
$34.39 (33.85%)
Buy Since 13-Mar-2025
$125
$28.27 (29.23%)
$130
1 months 7 days ago
(05-Aug-2026)
0/5 (0%)
$32.82 (35.60%)
Buy Since 04-Aug-2025
$130
$33.27 (34.39%)
$130
1 months 7 days ago
(05-Aug-2026)
3/5 (60%)
$37.82 (41.03%)
30
Buy Since 11-Mar-2025
$119
$22.27 (23.02%)
$126
2 months 4 days ago
(08-Jul-2026)
2/11 (18.18%)
$25.47 (27.23%)
25
What Year was the first public recommendation made by Yifeng Liu?